CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK
R Minaa, B Dhakalb, J San-Miguelc, N Lendvaid, M Vogele, K Lif, D Cheng, N Patelh, H Einselei, J Martinez-Lopezj
a University of Torino, Turin, Italy
b Medical College of Wisconsin, Milwaukee, United States
c Cancer Center Clínica Universidad Navarra, Pamplona, Spain
d Janssen Research & Development, Raritan, United States
e Janssen Research & Development, Neuss, Germany
f Janssen Research & Development, Spring House, United States
g Janssen Research & Development, Shanghai, China
h Legend Biotech USA Inc, Somerset, United States
i Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
j Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid, Spain
Ver másLido
381
Vezesque se leu este artigo
118
Total PDF
263
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 Maio | 1 | 1 | 2 |
| 2025 Abril | 34 | 9 | 43 |
| 2025 Março | 56 | 10 | 66 |
| 2025 Fevereiro | 31 | 13 | 44 |
| 2025 Janeiro | 39 | 15 | 54 |
| 2024 Dezembro | 36 | 17 | 53 |
| 2024 Novembro | 43 | 34 | 77 |
| 2024 Outubro | 23 | 19 | 42 |
